Clinical Trial Update: Subconjunctival Humira for Boston Keratoprosthesis [Phase 1]

View source ↗

Summary

Phase 1 clinical trial update assessing subconjunctival Humira (adalimumab) for patients with Boston Keratoprosthesis-related conditions; not yet recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Graft Failure
• Ocular Cicatricial Pemphigoid
• Penetrating Keratoplasty
• Stevens-johnson Syndrome

Drugs mentioned

• Humira (adalimumab)

Snippet

Sponsor: Massachusetts Eye and Ear Infirmary | Conditions: Penetrating Keratoplasty, Multiple Graft Failure | Phase 1 | Status: NOT_YET_RECRUITING